Heart Procedure Outperforms Medication for Atrial Fibrillation, Study Finds
A minimally invasive heart procedure developed by Boston Scientific has been shown to significantly outperform standard drug therapy in treating persistent atrial fibrillation (AFib), according to new clinical trial data. AFib, a common heart rhythm disorder, increases the risk of stroke fivefold and is associated with higher chances of heart failure and premature death. While…
AstraZeneca Commits $405 Million UK Investment Following U.S.-UK Pharma Pricing Agreement
London — AstraZeneca will invest £300 million ($405 million) in the United Kingdom, marking a renewed commitment to its home market after pausing major projects last year. The announcement was made by U.K. Prime Minister Keir Starmer, who linked the investment to a recently finalized U.S.-UK pharmaceutical pricing agreement. Investment Backed by Policy Shift The…
AbbVie Surpasses Q1 Expectations as New Immunology Drugs Offset Humira Decline
Chicago — AbbVie reported first-quarter results that exceeded Wall Street expectations, driven by strong demand for its newer immunology therapies Skyrizi and Rinvoq, as the company continues to transition beyond its former flagship drug Humira. The drugmaker posted adjusted earnings of $2.65 per share, ahead of analyst estimates of $2.59, while shares rose about 2%…
GE HealthCare Cuts Full-Year Profit Forecast as Inflation and Tariffs Weigh on Margins
Chicago — GE HealthCare lowered its full-year profit outlook after reporting first-quarter results impacted by rising inflation and tariff-related costs, sending its shares down დაახლოებით 13% in early trading. Profit Miss and Lowered Guidance The company reported adjusted earnings of $0.99 per share for the first quarter, falling short of analyst expectations of $1.05. The…
Align Technology Surpasses Q1 Expectations, Announces $200 Million Share Buyback
San Jose — Align Technology reported first-quarter results that exceeded Wall Street expectations, supported by sustained demand for its Invisalign clear aligners, and unveiled a $200 million share repurchase program, signaling confidence in its long-term growth trajectory. The stronger-than-expected performance drove the company’s shares up by as much as 4% in after-hours trading. Earnings Beat…
Biogen Beats Q1 Profit Estimates as Rare Disease Portfolio Gains Momentum
Boston — Biogen reported stronger-than-expected first-quarter results, driven by growing demand for its newer rare-disease and Alzheimer’s treatments, sending its shares up approximately 6%. The performance reflects the company’s ongoing shift away from legacy multiple sclerosis therapies toward a more diversified portfolio focused on high-growth therapeutic areas. Newer Therapies Offset Legacy Declines Biogen’s results were…
Regeneron Pharmaceuticals Beats Q1 Estimates on Dupixent Strength; Shares Fall on Eylea Concerns
New York — Regeneron Pharmaceuticals reported better-than-expected first-quarter revenue and profit, driven by strong demand for its blockbuster eczema treatment Dupixent. However, shares fell nearly 6% as investors reacted to ongoing challenges surrounding its eye drug Eylea. Dupixent Continues to Drive Growth The company’s performance was bolstered by robust sales of Dupixent, which Regeneron co-develops…
GSK Shares Fall Despite Strong Q1 as Investors Flag One-Off Boosts
London — Shares of GSK dropped more than 8% on Wednesday, as investors questioned the quality of the company’s first-quarter earnings despite results beating analyst expectations. The reaction comes early in the tenure of new CEO Luke Miels, who is under pressure to demonstrate sustainable growth and deliver on long-term strategic targets. Earnings Beat Overshadowed…
Eli Lilly Investors Seek Early Signals on Foundayo Launch as Obesity Drug Race Intensifies
New York — Investors in Eli Lilly are expected to focus less on first-quarter financial results and more on early commentary surrounding the launch of its new weight-loss pill, Foundayo, as the company reports earnings this week. Although U.S. sales of Foundayo began in early April, the drug’s performance will not yet be reflected in…
Why Healthcare Still Struggles to Scale Innovation
Healthcare is not lacking innovation. In fact, it is one of the most innovation-rich industries in the world. Breakthroughs in artificial intelligence, genomics, digital therapeutics, remote monitoring, and precision medicine are emerging at an unprecedented pace. New startups are constantly entering the ecosystem, and established institutions are investing heavily in research and development. Yet, despite…
The Illusion of Digital Transformation in Healthcare
Over the past decade, “digital transformation” has become one of the most frequently used—and often misunderstood—phrases in healthcare. Hospitals invest in new systems, clinics adopt electronic records, and health systems announce AI initiatives, all under the banner of transformation. Yet beneath the surface, many organizations are discovering an uncomfortable truth: despite significant investment, very little…
The Rise of “Invisible Healthcare”: Care Without Hospital Visits
Healthcare is quietly moving out of hospitals and into the background of everyday life. What once required appointments, travel, and physical interaction is increasingly happening through connected systems, digital platforms, and continuous monitoring. This shift is giving rise to what can be described as “invisible healthcare”—a model where care is delivered without the need for…